Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Recs

0
Player Avatar roalercoaster (60.41) Submitted: 3/29/2010 10:25:11 PM : Outperform Start Price: $5.22 PGNX Score: +49.41

Upcoming Catalyst

Featured Broker Partners


Advertisement